Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed pancreatic adenocarcinoma~  * Metastatic (stage IV) disease~* Measurable disease~* No symptomatic brain metastases~PATIENT CHARACTERISTICS:~* Karnofsky performance status 60-100%~* Not pregnant or nursing~* Adequate bone marrow, liver and kidney function~* No previous or concurrent malignancies at other sites except for surgically cured carcinoma in-situ of the cervix, basal cell or squamous cell carcinoma of the skin, or other neoplasms without evidence of disease within the past 5 years~* No multiple severe diseases which would compromise safety (i.e., cardiac failure, previous myocardial infarction within the past 4 months, cardiac arrhythmia, or history of psychiatric disabilities)~* No alcohol abuse~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy or metformin~* No other concurrent experimental drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PEXG regimen + metformin (Type: EXPERIMENTAL): cisplatin and epirubicin at 30 mg/mq on days 1 and 15, capecitabine at 1250 mg/mq days 1-28, gemcitabine at 800 mg/mq on days 1 and 15, Metformin at 2 g days 1-28
- PEXG regimen (Type: ACTIVE_COMPARATOR): cisplatin and epirubicin at 30 mg/mQ on days 1 and 15, capecitabine at 1250 mg/mq days 1-28, gemcitabine at 800 mg/mq on days 1 and 15

Based on this trial design, predict the completion outcome and termination type (if applicable).